AURA - NASDAQ
Aura Biosciences, Inc.
$6.90
-0.29%Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotAura Biosciences, Inc. Management Team
Mr. Conor Kilroy
Chief Legal Officer & Secretary
Compensation
$611,162
Dr. Jill J. Hopkins M.D.
Chief Medical Officer & President of Research and Development
Compensation
$761,250
Dr. Mark Plavsic D.V.M., Ph.D.
Chief Technology Officer
Dr. Elisabet de los Pinos Ph.D.
Founder, Chief Executive Officer, President & Director
Compensation
$948,209
Ms. Amy Elazzouzi
Interim Chief Financial Officer, Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer
Dr. Sabine Brookman-May
Senior Vice President & Therapeutic Area Head of Urologic Oncology
Mr. Patrick Nealon
Senior Vice President of Clinical Development Operations
Dr. Richard Mountfield Ph.D.
Senior Vice President of Regulatory Affairs & Quality
Dr. Anthony Daniels M.D.
Vice President & Therapeutic Area of Head Ocular Oncology
Aura Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $315K and sold $39.98M worth of AURA shares, resulting in $39.67M of net selling activity.
3 Months
0
0.00
6.9M
39.13M
-39.1M
-$39.13M
3-6 Months
0
0.00
123.1K
618.78K
-619K
-$619K
6-9 Months
0
0.00
39.2K
233.15K
-233K
-$233K
9-12 Months
51.0K
315.18K
1.1K
3.46K
+312K
+$312K
Top Buyers
Mattessich Antony C.
Director
$105K
Srivastava Sapna
Director
$105K
Johnson David Michael
Director
$105K
Top Sellers
Matrix Capital Management Company, Lp
10 Percent Owner
$39.04M
De Los Pinos Elisabet
Director, Officer: See Remarks
$381K
Hopkins Janet Jill
Officer: Chief Medical Officer
$196K
Plavsic Mark
Officer: Chief Technology Officer
$158K
Kilroy Conor
Officer: See Remarks
$143K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $39.67M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
AURA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 15, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.